AstraZeneca logs upbeat trial results from Covid drug

A logo is pictured on a wall outside the offices of pharmaceutical company AstraZeneca in Macclesfield, central England on May 11, 2021. – British pharmaceuticals giant AstraZeneca said Friday that its Covid vaccine generated $275 million (227 million euros) in sales in the first quarter, as its chief executive defended the company’s performance in the face of EU legal action. (Photo by Paul ELLIS / AFP)

LONDON, United Kingdom (AFP) – British pharmaceuticals giant AstraZeneca on Monday revealed more positive results from a trial of a treatment for Covid-19 symptoms.

The drug, made from a combination of two antibodies, achieved a “statistically significant reduction in severe Covid-19 or death” in non-hospitalised patients with mild-to-moderate symptoms, AstraZeneca said in a statement.

The group’s treatment, known as AZD7442, has been undergoing phase 3 or final clinical trials to assess its safety and efficacy.

“With continued cases of serious Covid-19 infections across the globe, there is a significant need for new therapies like AZD7442 that can be used to protect vulnerable populations … and can also help prevent progression to severe disease,” said principal trial investigator Hugh Montgomery.

“These positive results show that a convenient intramuscular dose of AZD7442 could play an important role in helping combat this devastating pandemic.”

An illustration picture shows a drop from a syringe with the logo of British pharmaceutical company AstraZeneca on November 17, 2020. (Photo by JUSTIN TALLIS / AFP)

The trial involved 903 participants and 90 percent of them were people at high risk of progression to severe Covid-19.

AstraZeneca’s separate Covid vaccine, developed with the University of Oxford, helped enable Britain’s speedy Covid vaccination drive.